Stock Events

PhaseBio Pharmaceuticals 

$0
4
+$0+0% Today

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
750
Avg. Volume
0
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

18JanExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q4 2022
-0.9
-0.68
-0.45
-0.23
Expected EPS
-0.35
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHASQ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biotechnology company that develops and manufactures innovative human therapeutics, including treatments for cardiovascular diseases, which competes with PhaseBio's focus on cardiopulmonary disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals focuses on developing medications for serious medical conditions, including cardiovascular diseases, directly competing with PhaseBio's product pipeline.
Novo Nordisk
NVO
Mkt Cap445.94B
Novo Nordisk is a global healthcare company with a strong focus on diabetes and obesity management, but also on hemostasis management, which overlaps with PhaseBio's interest in bleeding disorders.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including areas like cardiovascular health, competing with PhaseBio's therapeutic areas.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical corporation with a broad range of products in various therapeutic areas, including cardiovascular diseases, making it a competitor to PhaseBio.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca operates in several therapeutic areas, including cardiovascular, renal, and metabolism, directly competing with PhaseBio's focus areas.
Merck &
MRK
Mkt Cap318.55B
Merck is known for its contributions to healthcare, including cardiovascular disease treatments, positioning it as a competitor to PhaseBio.
Sanofi
SNY
Mkt Cap128.21B
Sanofi focuses on a broad spectrum of therapeutic areas, including cardiovascular diseases, which makes it a direct competitor to PhaseBio.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its Janssen Pharmaceuticals companies, develops treatments for a wide range of health conditions, including cardiovascular diseases, competing with PhaseBio.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie has a diverse line of therapies, including interest in cardiovascular diseases, making it a competitor to PhaseBio in the pharmaceutical landscape.

About

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Show more...
CEO
Jonathan Mow
Employees
60
Country
US
ISIN
US7172241090
WKN
000A2N7LU

Listings